Prevalence and predictors of diabetes distress among adults with type 2 diabetes mellitus: a facility-based cross-sectional study of Bangladesh

A. B. M. Kamrul-Hasan 1*, Mohammad Abdul Hannan 2, Md Asaduzzaman 3, Mohammad Motiur Rahman 4, Muhammad Shah Alam 5, Mohammad Nurul Amin 6, Mohammed Ruhul Kabir 7, Palash Kumar Chanda 8, Nadia Janna 9, Md Zahirul Haque 10, Sanjoy Ranjon Banik 8, Mohammad Jahid Hasan 11* and Shahjada Selim 12

Abstract

Introduction: Diabetes distress (DD) is common and has considerable impacts on diabetes management. Unfortunately, DD is less discussed and frequently underestimated. This study evaluated the prevalence and predictors of DD in adults with type 2 diabetes mellitus (T2DM).

Methods: A cross-sectional study was conducted at several specialized endocrinology outpatient clinics in Bangladesh from July 2019 to June 2020; 259 adults with T2DM participated. Participants’ DD and depression were measured using the 17-item Diabetes Distress Scale (DDS-17) and 9-item Patient Health Questionnaire (PHQ-9), respectively. DDS-17 scores $\geq 2$ and PHQ-9 scores $\geq 10$ were the cutoffs for DD and significant depression, respectively.

Results: The mean (±SD) age of the participants was 50.36 (±12.7) years, with the majority (54.8%) being male; their median (IQR) duration of diabetes was 6 (3–11) years. Among the study participants, 52.5% had DD (29.7% moderate and 22.8% high DD). The prevalence of emotional burden, physician-related distress, regimen-related distress, and interpersonal distress was 68.7, 28.6, 66, and 37.7%, respectively. Depression was present in 40.5%; 28.6% of the participants had DD and depression. The total DDS-17 score was positively correlated with the PHQ-9 score ($r = 0.325$, $p < 0.001$). Rural residence (OR 1.94), presence of any diabetic complication (OR 3.125), insulin use (OR 2.687), and presence of major depression (OR 4.753) were positive predictors of DD. In contrast, age $\geq 40$ years at diabetes diagnosis (OR 0.047) and diabetes duration of $> 10$ years (OR 0.240) were negative predictors of DD ($p < 0.05$ in all instances).

Conclusions: The prevalence of DD in our setting is notably high; DD and depression frequently overlap. Screening for diabetes distress may be considered, especially in high-risk patients.

Keywords: T2DM, Diabetes distress, Depression, DDS-17, PHQ-9

* Correspondence: rangassmc@gmail.com; dr.jahid61@gmail.com

1Department of Endocrinology, Mymensingh Medical College, Mymensingh
2207, Bangladesh
11Pi research consultancy center, Dhaka, Bangladesh
Full list of author information is available at the end of the article

© The Author(s). 2022 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
The term ‘diabetes distress’ (DD) refers to an emotional response characterized by extreme apprehension, discomfort, or dejection due to the perceived inability to cope with the challenges and demands of living with diabetes mellitus (DM) [1]. DD includes a wide range of emotions, such as negative feelings, anger, fear, guilt, frustration, and shame, that may arise from the negative emotional burden of diabetes and concerns of the patient about blood sugar control, existing comorbidity, presence of complications, the indication of complications, and access to treatments [2, 3]. DD is a common psychological state found in persons with DM and their caregivers [1]. A meta-analysis found an overall prevalence of 36% for DD in patients with type 2 DM (T2DM) [2]. DD has a negative association with a healthy lifestyle, self-management, self-efficacy, self-care, and adherence to the recommended treatment regimen, leading to worsening T2DM [2, 4, 5]. It is also directly related to cardiovascular disorders and high mortality [6, 7]. Depression is also highly prevalent in T2DM and is associated with poor glycemic control, higher rates of complications, and mortality in these patients [8, 9].

Although depression and DD are distinct conditions, DD considerably overlaps with the symptoms of major depression [10]. It is hypothesized that DD is at the milder end (but specific to diabetes), and depression is at the more extreme but general end of the spectrum of mental health problems [10]. The coexistence of the two conditions is not uncommon, and the prevalence of diabetes distress is higher in samples with a higher prevalence of comorbid depressive symptoms [2]. Management of DD is nonpharmacological, emphasizing empathic and confidence-building communication by members of the diabetes care team, whereas major depression frequently warrants drug treatment [1].

In Bangladesh, 8.4 million adults lived with diabetes in 2019 and are projected to double by 2045 [11]. Although some studies have been conducted relating T2DM and depression here, data are scarce exploring the prevalence of DD and factors associated with DD [12, 13]. This multicenter, clinic-based study was conducted to fill this knowledge gap.

Materials and methods
Ethical considerations
The Institutional Review Board of Mymensingh Medical College, Mymensingh, Bangladesh provided ethical approval for this study. All eligible participants were informed of the study’s aims and details about the study procedures. Informed written consent was ensured before final inclusion. As stated in the Declaration of Helsinki, the principles of biomedical research were followed while conducting the study.

Study settings and participants
This cross-sectional study was conducted at several specialized endocrinology outpatient clinics in Bangladesh from July 2019 to June 2020. A convenient sampling strategy was performed on all adult patients diagnosed with T2DM for at least one year to collect samples. Exclusion criteria were type 1 diabetes, pregnancy, lactation, acute illness, any previously diagnosed psychiatric disorder, dementia, use of psychotropic medications, use of medications that may impair memory or cognition, and experience an unpleasant event such as a relative’s death during the prior three months.

Demographic and clinical variables
The variables of age, gender, residence, education level, monthly income, smoking status, diabetes in first-degree relatives, age at diagnosis of DM, duration of DM, type of glucose-lowering medications, presence of diabetic complications, and comorbid illness were documented by a predesigned questionnaire and were completed by patients in a quiet room.

Participants’ physical activity-related information was documented using the Global Physical Activity Questionnaire (GPAQ) version 2. It collects information on physical activity participation in three settings (or domains), e.g., activity at work, travels to and from places, recreational activities, and sedentary behavior, comprising 16 questions. The total time spent in physical activity during a typical week and the intensity of the physical activity were considered to calculate a categorical indicator. Throughout a week, including activity for work, during transport, and leisure time, adults should do at least an equivalent combination of moderate- and vigorous-intensity physical activity achieving at least 600 MET (metabolic equivalents)-minutes [14]. The Perceived Dietary Adherence Questionnaire (PDAQ) was used to measure the participants’ perceptions of their dietary adherence. The PDAQ consists of nine questions focusing on the consumption of foods during the previous seven days. The response is based on a seven-point Likert scale to answer the question. The total score quantified the extent to which individuals perceived themselves as adhering to dietary guidelines, with higher scores indicating higher perceived adherence [15].

Standing height was measured to within 1 mm without shoes using wall-mounted stadiometers. Body weight, standing height, and waist circumference were measured, and body mass index (BMI) was calculated. We used BMI categories applicable to Asian Indians to determine the obesity status; WC ≥90 cm in males and ≥80 cm in females was the cutoff for abdominal obesity [16]. Recent (within the preceding month) HbA1c, serum creatinine, urine routine examination (R/E), and fasting lipid profile were retrieved from participants’
medical records. An HbA1c < 7% was defined as controlled DM. The estimated glomerular filtration rate (eGFR) was calculated using the CKD-EPI formula. An eGFR < 60 ml/min/1.73 m² and/or albuminuria in urine R/E was defined as chronic kidney disease. Dyslipidemia was defined according to cutoffs described in the Adult Treatment Panel (ATP) III guidelines [17].

Assessment of diabetes distress
Diabetes distress was measured using the 17-item Diabetes Distress Scale (DDS-17) [18]. The DDS-17 assesses diabetes-related difficulties and problems during the preceding month on a Likert scale ranging from 1 (no problem) to 6 (serious problem) [18]. The DDS provides a total DD score and four subscale scores, addressing emotional burden (five items), physician-related distress (four items), regimen-related distress (five items), and diabetes-related interpersonal distress (three items). Each subscale was scored separately by dividing the sum of its item scores by the number of items. Additionally, the mean total distress score was calculated by calculating the sum of the 17 items and dividing by 17. A mean item score of < 2.0 indicates little or no distress, 2.0–2.9 indicates moderate distress, and ≥ 3.0 indicates high distress [19]. DD was considered a dichotomous variable in this study, with patients considered to have DD if DDS-17 scores were ≥ 2.

Assessment of depression
Depression in the participants was measured by the 9-item Patient Health Questionnaire (PHQ), which refers to symptoms experienced during the last two weeks [20]. The PHQ-9 uses a four-point Likert scale ranging from 0 (not at all) to 3 (most days) for each question, the frequency with which they have experienced specific depression symptoms in the preceding two weeks, with a total score ranging from 0 to 27. PHQ-9 scores with cut-off points of 5, 10, 15, and 20 represent mild, moderate, moderately severe, and severe depression, respectively [20]. A PHQ-9 score ≥ 10 was found to have a sensitivity of 88% and a specificity of 88% for major depression [21]. In this study, depression was considered a dichotomous variable, with patients deemed significant depression if PHQ-9 scores were ≥ 10.

Statistical analysis
We analyzed data using Statistical Product and Service Solutions version 26.0 software (IBM Corp. Released 2019, IBM SPSS Statistics for Windows, Version 26.0, Armonk, NY: IBM Corp). Categorical variables are represented as percentages, and continuous variables are presented as the mean ± standard deviation (SD) or median (interquartile range, IQR). Student’s t test, Chi-square test, and Mann–Whitney U test were performed to compare the variables between participants with no DD and those with DD (moderate and high). Pearson correlation test measured correlations between total DDS score and PHQ-9 score. Bivariate logistic regression analysis was performed to determine the risk factors for DS. A P value < 0.05 was considered statistically significant.

Results
Baseline characteristics of participants
Data from 259 adults with T2DM were analyzed. The mean age was 50.36 (±12.7) years, 54.8% were male, 62.5% came from urban areas, 37.8% had a higher secondary or above level of education, 8.1% were current smokers, 66.8% had a first-degree relative with DM, and 62.9% were overweight/obese. The median duration of diabetes was 6 (3–11) years, 44.4% received insulin, the mean HbA1c was 8.12% (±2.3), and 68% had uncontrolled diabetes. All but one (99.6%) had dyslipidemia, 61% had diabetic complication(s), and 39.8% had comorbid disease(s). Of them, 66.8% met WHO recommendations for physical activity; the mean total PDAQ score was 29.74 (±10.5).

Prevalence of DD and depression
Among the study participants, 52.5% had DD (29.7% moderate and 22.8% high DD). Emotional burden was the most crucial domain in total DD, presenting in 68.7% of the participants, followed by regimen-related distress (66%), interpersonal distress (37.7%), and physician-related distress (28.6%) (Fig. 1). Depression (PHQ-9 score ≥ 10) was present in 40.5% of the participants (moderate, moderately severe, and severe depression 27.4, 8.1, and 5%, respectively) (Fig. 2). A total of 28.6% of the participants had both DD and depression. The total DDS score had significant positive correlations (r = 0.325, p < 0.001) with the PHQ-9 score. The distribution of depression within diabetes distress categories is depicted in Fig. 3. DD was present in 70.5%
of the participants with depression, whereas among those with moderate and high DD, 54.4% had depression; 62.5% of those with high DD also had depression.

Factors associated with DD
A comparison of the variables between participants with no DD with moderate and severe DD is shown in Table 1. HbA1c, PHQ-9 score, frequencies of insulin use, participants with uncontrolled diabetes, participants with at least one diabetic complication, participants not meeting WHO recommendations for physical activity, and participants with depression were higher in the moderate and severe distress groups than in the no diabetic distress group; eGFR was lower in the moderate and severe distress groups. Participants in the two groups were similar in age, duration of DM, BMI, WC, serum creatinine, serum lipids, PQAQ scores, and the frequencies of male participants, current smoker, first-degree relative(s) with DM, overweight/obesity, abdominal obesity, and comorbidity.

In bivariate logistic regression analysis, rural residence (OR 1.940), presence of any diabetic complication (OR 3.125), insulin use (OR 2.687), and presence of major depression (OR 4.753) were associated with greater odds of DD, whereas higher age (≥40 years) at diabetes diagnosis (OR 0.403) and longer duration (>10 years) of diabetes (OR 0.240) were associated with lower odds of DD (Table 2).

Discussion
In our sample of patients with T2DM presenting to endocrine clinics of several hospitals in Bangladesh, we found that almost half of the patients suffered from diabetes distress, depression and a combination of DD and depression.

The variable prevalence of DD and depression in T2DM has been reported from different countries, and the prevalence greatly varies with demographics, geographical region, and cultural backgrounds. Even the cutoffs for defining DD and depression also influence their prevalence [2]. In Bangladesh, a single-center study at a tertiary hospital observed a 48.5% prevalence of DD using the same DDS-17 scale and cutoffs similar to this study to define DD [22]. The prevalence of DD was 49.2% in Malaysia, 29.4% in Vietnam, 51.3% in the USA, and 39% in Canada using the same tool and cutoffs [7, 23–25]. Forty-two percent of the population was depressed in Malaysia using the cutoff PHQ-9 score ≥5 [23], and 15.3% of the study subjects had major depression (PHQ ≥10) using the PHQ-8 questionnaire [7]. Emotional burden (68.7%) and regimen-related distress (66%) were more important domains than interpersonal distress (37.7%) and physician-related distress (28.6%) in measuring DD. Similar observations were found in another context [9, 22, 24].

One-fourth of the participants had DD and major depression. Major depression was present in 70.5% of patients with DD. In contrast, 54.4% had major depression among those with DD. Major depression was associated with a greater risk of DD. Tenets of DD overlap with the symptoms of major depression; depression amplifies the psychological impact of diabetes diagnosis, resulting in increased DD [26]. Various combinations of DD and depression were present in multiple studies in different locations [7, 23]. Nanayakkara et al. and Chew et al. identified depression as a risk factor for diabetes distress, which corroborates with our studies [9, 23]. This phenomenon was also supported by a meta-analysis [2]. Both DD and depression are driven by shared underlying biological and behavioral mechanisms, such as hypothalamic–pituitary–adrenal axis activation, inflammation, sleep disturbance, inactive lifestyle, poor dietary habits,
| Variables                          | Subgroups | All subjects (N = 259) | Without DD (DDS < 2) (n = 123) | With DD (DDS ≥ 2) (n = 136) | p value |
|-----------------------------------|-----------|------------------------|---------------------------------|---------------------------|---------|
| Age (years)                       |           | 50.36 ± 12.7           | 50.50 ± 11.9                   | 50.22 ± 13.4             | 0.858   |
| Age group                         | < 50 years| 121 (46.7)             | 58 (47.2)                      | 63 (46.3)                | 0.901   |
|                                   | ≥ 50 years| 138 (53.3)             | 65 (52.8)                      | 73 (53.7)                |         |
| Gender                            | Male      | 142 (54.8)             | 72 (58.5)                      | 70 (51.5)                | 0.263   |
|                                   | Female    | 117 (45.2)             | 51 (41.5)                      | 66 (48.5)                |         |
| Residence                         | Urban     | 162 (62.5)             | 86 (69.9)                      | 76 (55.9)                | 0.021   |
|                                   | Rural     | 97 (37.5)              | 37 (30.1)                      | 60 (44.1)                |         |
| Monthly income category (in BDT)  | < 20,000  | 99 (38.2)              | 46 (37.4)                      | 53 (39.0)                | 0.482   |
|                                   | 20,000-40,000 | 107 (41.3) | 55 (44.7) | 52 (38.2) |
|                                   | ≥ 40,000  | 53 (20.5)              | 22 (17.9)                      | 31 (22.8)                |         |
| Education                         | < Higher secondary | 161 (62.2) | 74 (60.2) | 87 (64) |
|                                   | ≥ Higher secondary | 98 (37.8)  | 49 (39.8) | 49 (36)   | 0.608   |
| Current smoker                    | No        | 238 (91.9)             | 111 (90.2)                     | 127 (93.4)               | 0.373   |
|                                   | Yes       | 21 (8.1)               | 12 (9.8)                       | 9 (6.6)                  |         |
| DM in First-Degree Relative       | No        | 86 (33.2)              | 41 (33.3)                      | 45 (33.1)                | 1.000   |
|                                   | Yes       | 173 (66.8)             | 82 (66.7)                      | 91 (66.9)                |         |
| Age at diagnosis of DM            | < 40 years| 105 (40.5)             | 46 (37.4)                      | 59 (43.4)                | 0.375   |
|                                   | ≥ 40 years| 154 (59.5)             | 77 (62.6)                      | 77 (56.6)                |         |
| Duration of DM (years)            | 1–5 years | 6 (3–11)               | 6 (2–11)                       | 5.5 (3–10)               | 0.967   |
|                                   | > 5–10 years | 65 (25.1)  | 29 (23.6) | 36 (26.5) |
|                                   | > 10 years | 65 (25.1)              | 33 (26.8)                      | 32 (23.5)                |         |
| BMI (kg/m²)                       |           | 24.04 ± 3.3            | 24.16 ± 2.7                    | 23.9 ± 3.7               | 0.560   |
| Overweight or obese               |           | 163 (62.9)             | 80 (65)                        | 83 (61)                  | 0.522   |
| WC (cm)                           | 87.2 ± 9.3 | 87.9 ± 7.8             | 86.6 ± 10.5                     | 0.271   |
| Abdominal obesity                 | 161 (62.2) | 78 (63.4)              | 83 (61)                        | 0.702   |
| HbA1c (%)                         | 8.12 ± 2.3 | 7.72 ± 2.0             | 8.49 ± 2.5                      | 0.008   |
| Control of DM                     | Controlled | 83 (32)                | 48 (39)                        | 35 (25.7)               | 0.024   |
|                                   | Uncontrolled | 176 (68)              | 75 (61)                        | 101 (74.3) |
| Treatment of DM                   | Lifestyle only | 5 (1.9)               | 1 (0.8)                        | 4 (2.9)                  | < 0.001 |
|                                   | Lifestyle + OAD | 139 (53.7)        | 84 (68.3)                      | 55 (40.4)               |
|                                   | Lifestyle + insulin | 65 (25.1)       | 23 (18.7)                      | 42 (30.9)               |
|                                   | Lifestyle + OAD + insulin | 50 (19.3) | 15 (12.2) | 35 (25.7) |
| Serum creatinine (mg/dL)          |           | 0.9 (0.8–1.2)          | 0.9 (0.8–1.2)                  | 0.95 (0.8–1.2)           | 0.643   |
| Estimated GFR (mL/min/1.73 m²)    | 81.9 (60.1–101.4) | 86.5 (60.5–102.1) | 79.0 (58.6–98.7)               | 0.040   |
| Total cholesterol (mg/dL)         |           | 197.4 ± 39.1           | 198.8 ± 36.8                   | 196.2 ± 41.2             | 0.589   |
| HDL cholesterol (mg/dL)           |           | 39.9 ± 7.5             | 40.4 ± 6.6                     | 39.4 ± 8.2               | 0.255   |
| LDL cholesterol (mg/dL)           |           | 127.3 ± 34.7           | 127.7 ± 33.7                   | 126.9 ± 35.6             | 0.836   |
| Triglyceride (mg/dL)              |           | 188.9 ± 60.9           | 179.9 ± 59.9                   | 197.1 ± 60.9             | 0.023   |
| Dyslipidemia                       |           | 258 (99.6)             | 123 (100)                      | 135 (99.3)               | 1.000   |
| Any diabetic complication         |           | 158 (61)               | 56 (48.8)                      | 98 (72.1)                | < 0.001 |
| Nephropathy                        |           | 92 (35.5)              | 36 (29.3)                      | 56 (41.2)                | 0.052   |
and environmental and cultural risk factors [27]. Concurrent depression and DD may aggravate functional impairment, self-management problems, poorer glycemic control, increased risk of diabetes complications, and poorer quality of life [26].

In this study, age difference was not a predictor of DD. Several studies showed that patients in the higher age group had higher DD risks, but few studies also found no significant difference between different age groups [3, 28]. Younger age was associated with a higher DDS score stated by Chew et al. [23] and could be explained by the stressors of family responsibilities, work, and financial challenges. Factors associated with DD in elderly individuals could be difficulties in self-care, comorbidities, disability and lack of social support. Therefore, the relationship of DD with age is not straightforward and interacts with other risk factors for DD.

Similar to Huynh et al., we observed no influence of gender on the risk of DD [24]. However, few studies have reported that women are at higher risk of DD [2, 3, 9]. Women tend to have greater stress reactivity to various situations, such as stressful life and work events [25]. In the current study, residence in rural areas appeared to be a risk factor for DD. Todalabagi et al.’s observations in the Indian population support this finding [29]. Tertiary care services are only available in larger cities of Bangladesh; residing in remote rural areas may result in the feeling of deprivation of adequate support from healthcare systems, which may potentiate distress. Another factor that potentiates DD was the duration of disease, and participants with DM for > 10 years had a lower risk of DD than those with DM for 1–5 years [3, 24]. As the disease progresses, there is improvement in adjusting to the disease, learning disease management skills, and increasing patients’ awareness of the disease.

Although a negative relation was found between insulin use and DD [3], a number of studies supported that insulin use poses a higher risk of DD [9, 22], and our study also explored a similar phenomenon.

Most of our participants with and without DD had uncontrolled diabetes, which may be responsible for the failure to establish uncontrolled diabetes as a risk factor for DD. DD leads to poorer self-management and medication adherence, resulting in a higher HbA1c. On the other hand, failure to achieve glycemic control may result in feelings of ‘diabetes burnout’ and increased diabetes distress. Distress is greatly enhanced with an increasing number of complications [3, 9, 22]. The presence of complications leads to many concerns, including the cost of management, the impact on daily lifestyle, employment, relationships, etc., for patients with DM; all these may adversely affect psychological wellbeing and be associated with higher distress [6]. We did not measure the type and number of comorbidities and could not infer whether a higher number of comorbidities and specific comorbid conditions were associated with DD in our participants.

Similar to Azadbakht et al., our study did not find any influence of overweight/obesity on the risk of DD. Obesity was associated with a higher risk of DD,

### Table 1 Sociodemographic, clinical, and biochemical characteristics of the participants according to the DD categories (N = 259) (Continued)

| Variables Subgroups | All subjects (N = 259) | Without DD (DDS < 2) (n = 123) | With DD (DDS ≥ 2) (n = 136) | p value |
|---------------------|------------------------|---------------------------|-------------------|--------|
| Retinopathy         | 48 (18.5)              | 16 (13)                   | 32 (23.5)         | 0.037  |
| Neuropathy          | 64 (24.7)              | 22 (17.9)                 | 42 (30.9)         | 0.021  |
| IHD                 | 44 (17.0)              | 21 (17.1)                 | 23 (16.9)         | 1.000  |
| Stroke              | 5 (1.9)                | 3 (2.4)                   | 2 (1.5)           | 0.671  |
| Foot ulcer          | 9 (3.5)                | 2 (1.6)                   | 7 (5.1)           | 0.177  |
| Recurrent infections| 24 (9.3)               | 5 (4.1)                   | 19 (14)           | 0.009  |
| Any comorbidity     | 103 (39.8)             | 49 (39.8)                 | 54 (39.7)         | 1.000  |
| HTN                 | 91 (35.1)              | 46 (37.4)                 | 45 (33.1)         | 0.515  |
| Meets WHO recommendations on physical activity | Yes | 173 (66.8) | 90 (73.2) | 83 (61) | 0.047 |
|                     | No                     | 86 (33.2)                 | 33 (26.8)         | 53 (39) |
| PDAQ Total Score    | 29.74 ± 10.5           | 30.68 ± 10.6              | 28.89 ± 10.3      | 0.169  |
| PHQ-9 Score         | 8.54 ± 5.8             | 6.98 ± 5.2                | 9.96 ± 5.4        | <0.001 |
| Major depression    | Absent                 | 154 (59.5)                | 92 (74.8)         | 62 (45.6) |
|                     | Present                | 105 (40.5)                | 31 (25.2)         | 74 (54.4) |

p values by Student’s t test, Chi-square test, or Mann–Whitney U test as applicable

BDT Bangladeshi Taka, BMI Body mass index, WC Waist circumference, HDL High-density lipoprotein, LDL Low-density lipoprotein, IHD Ischemic heart disease, HTN Hypertension
according to Islam et al. [22]. Obesity stigma is related to psychological distress; obese people may have negative body images and need extra care in dieting, exercise, and weight-loss medications beyond their diabetes management; all these factors may accelerate distress in them.

Limitations of the study
The study’s cross-sectional design limits its ability to judge the causality of the relationships. Some critical variables correlated with DD were not measured, e.g., employment, marital status, family and social support, insurance status, number of prescribed drugs, attended

| Variables                      | Subgroups          | Odds Ratio (95% Confidence Interval) | p value |
|--------------------------------|--------------------|--------------------------------------|---------|
| Age Group                      | < 50 years         | Referent                             |         |
|                                | ≥ 50 years         | 1.808 (0.735–4.448)                  | 0.197   |
| Gender                         | Male               | Referent                             |         |
|                                | Female             | 0.926 (0.462–1.860)                  | 0.830   |
| Residence                      | Urban              | Referent                             |         |
|                                | Rural              | 1.940 (1.003–3.752)                  | 0.049   |
| Income Category (in BDT)       | < 20,000           | Referent                             |         |
|                                | 20,000 to < 40,000 | 0.965 (0.483–1.927)                  | 0.920   |
|                                | 40,000 and Above   | 2.199 (0.846–5.718)                  | 0.106   |
| Education Category             | Up to Secondary    | Referent                             |         |
|                                | ≥ Higher Secondary | 1.042 (0.484–2.242)                  | 0.917   |
| Current Smoker                 | No                 | Referent                             |         |
|                                | Yes                | 0.318 (0.100–1.010)                  | 0.052   |
| T2DM in the First-Degree Relative | No               | Referent                             |         |
|                                | Yes                | 1.145 (0.595–2.204)                  | 0.686   |
| Age at DM Diagnosis            | < 40 years         | Referent                             |         |
|                                | 40 years or above  | 0.403 (0.164–0.988)                  | 0.047   |
| T2DM Duration                  | 1–5 years          | Referent                             |         |
|                                | > 5–10 years       | 0.701 (0.325–1.512)                  | 0.365   |
|                                | > 10 years         | 0.240 (0.100–0.577)                  | 0.001   |
| Overweight or Obese            | No                 | Referent                             |         |
|                                | Yes                | 0.561 (0.293–1.074)                  | 0.081   |
| Abdominal Obesity              | No                 | Referent                             |         |
|                                | Yes                | 1.078 (0.552–2.108)                  | 0.902   |
| Glycemic Status                | HbA1c < 7%         | Referent                             |         |
|                                | HbA1c ≥ 7%         | 1.071 (0.546–2.101)                  | 0.825   |
| Any Diabetic Complication      | Absent             | Referent                             |         |
|                                | Present            | 3.125 (1.546–6.320)                  | 0.002   |
| Any Comorbidity                | Absent             | Referent                             |         |
|                                | Present            | 0.602 (0.301–1.204)                  | 0.151   |
| PDAQ total score               |                    |                                      |         |
|                                |                    | 0.993 (0.964–1.022)                  | 0.619   |
| Meets WHO recommendations on physical activity | Yes | Referent |         |
|                                | No                 | 1.781 (0.921–3.444)                  | 0.086   |
| Injects Insulin                | No                 | Referent                             |         |
|                                | Yes                | 2.687 (1.414–5.105)                  | 0.003   |
| Major Depression               | Absent             | Referent                             |         |
|                                | Present            | 4.753 (2.466–9.162)                  | < 0.001 |
healthcare facilities, etc. The sample size was also small. The study was conducted in specialized endocrinology centers, which usually deal with more complex referred patients; therefore, the study result may not generalize to all patients with T2DM. Although the DDS and PHQ-9 are widely used tools for measuring DD and depression, respectively, they are not validated in our setting, and only one scale was used to assess the patients. Nevertheless, this is the first multicenter study in Bangladesh exploring the prevalence and associated factors of diabetes distress in the background of alarmingly increasing diabetes prevalence in the country. A wide-scale longitudinal study in this field can better explain the existing relationships between DD and other variables.

Conclusion
Our study shows that diabetes distress is highly prevalent in our patients with T2DM. Lower age at diabetes diagnosis, rural residence, shorter duration of diabetes, presence of any diabetic complication, insulin use, and presence of major were the risk factors for DD observed in this study. The study results endorsed the need for clinical attention to DD, especially in countries with a high prevalence of T2DM, such as Bangladesh, for comprehensive and effective diabetes care.

Acknowledgments
We acknowledged the supporting role of the hospital authorities and auxiliary staff for their help during the research work.

Authors’ contributions
Conceptualization: ABMKH, MAH, MMR, MSA, MNA, MRK, PKC, NJ, MZH, SRB, MJH, SS. Data Curation: ABMKH, MAH, MA, MMR, MSA, MNA, SS. Formal Analysis: ABMKH, MAH, MMR, PKC, NJ, MZH, SRB, MJH, SS. Investigation: ABMKH, MAH, MA, MMR, MSA, MNA, MRK, PKC, NJ, MZH, SRB, MJH, SS. Methodology: ABMKH, MAH, MA, MMR, MSA, MNA, MRK, PKC, NJ, MZH, SRB, MJH, SS. Project Administration: ABMKH, MAH, MA, MMR, Resources: ABMKH, MAH, MA, MMR, MSA, MNA, MRK, PKC, NJ, MZH, SRB, MJH, SS. Supervision: ABMKH, SS. Visualization: ABMKH, MAH, MA, MMR, MSA, MNA, MRK, PKC, NJ, MZH, SRB, MJH, SS. Writing – Original Draft Preparation: ABMKH, MAH, MA, MMR, MSA, MNA, MRK, PKC, NJ, MZH, SRB, MJH, SS. Writing – Review & Editing: ABMKH, MAH, MA, MMR, MSA, PKC, NJ, MZH, SRB, MJH, SS. Correspondence: ABMKH and MJH. All authors read and approved the final manuscript.

Funding
The authors received no funding from an external source for this study.

Availability of data and materials
The data used to support this study are available from the corresponding author upon request (rangassmc@gmail.com).

Declarations
Ethics approval and consent to participate
The study protocol was reviewed and approved by the Institutional Review Board of Mymensingh Medical College, Mymensingh, Bangladesh. Informed written consent was taken from the patients before participation. The current declaration of Helsinki was followed during the study work.

Consent for publication
None required.

Competing interests
None to declare.

Author details
1. Department of Endocrinology, Mymensingh Medical College, Mymensingh, Bangladesh. 2. Department of Endocrinology, North East Medical College, Sylhet, Bangladesh. 3. Department of Endocrinology, Shaheed Sheikh Abu Naser Specialized Hospital, Khulna, Bangladesh. 4. Department of Medicine, Rajshahi Medical College Hospital, Rajshahi, Bangladesh. 5. Department of Medicine, Army Medical College, Cumilla, Bangladesh. 6. Department of Endocrinology, Mugda Medical College, Dhaka, Bangladesh. 7. Department of Medicine, Sylhet MAG Osmani Medical College, Sylhet, Bangladesh. 8. Department of Endocrinology, Mymensingh Medical College Hospital, Mymensingh, Bangladesh. 9. Department of Endocrinology, Alok Healthcare & Hospital Ltd., Dhaka, Bangladesh. 10. Department of Chronic Diseases, Government Homeopathic Medical College, Dhaka, Bangladesh. 11. Pi research consultancy center, Dhaka, Bangladesh. 12. Department of Endocrinology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.

Received: 26 May 2021 Accepted: 10 January 2022
Published online: 23 January 2022

References
1. Kafka S, Verma K, Balhara Y. Diabetes distress. J Soc Health Diabetes. 2018;06(01):004–7. http://www.thieme-connect.de/D/O/DOI/10.1055/s-0038-1676185.
2. Perrin NE, Davies MJ, Robertson N, Snoek FJ, Khunti K. The prevalence of diabetes-specific emotional distress in people with type 2 diabetes: a systematic review and meta-analysis. Diabet Med. 2017;34(11):1508–20. https://doi.org/10.1111/dme.13448.
3. Azadbakht M, Taheri Tanjani P, Fadayevatan R, Froughan M, Zanjari N. The prevalence and predictors of diabetes distress in elderly with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2020;163:108133. https://doi.org/10.1016/j.diabres.2020.108133.
4. Gonzalez JS, Shreck E, Psaros C, Safren SA. Distress and type 2 diabetes-treatment adherence: a mediating role for perceived control. Health Psychol. 2015;34(5):505–13. http://doi.apa.org/getdoi.cfm?doi=10.1037/hea0000131.
5. Beléndez Vázquez M, Lorente Armendáriz I, Maderuelo LM. Estrés emocional y calidad de vida en personas con diabetes y sus familiares. Gac Sanit. 2015; 29(4):300–3. https://linkinghub.elsevier.com/retrieve/pii/S0165185815300024.
6. Youn YG, Kong JE, Kim KH, Park HM, Lee KB, Kim D. Prevalence of diabetes distress and cardiovascular complication risks in patients with type 2 diabetes and lower socioeconomic status: a pilot study. Diabetes Spectr. 2019;32(3):257–63 https://spectrum.diabetesjournals.org/lookup/doi/10.1337/ds18-0023.
7. Fisher L, Glasgow RE, Stucky LA. The relationship between diabetes distress and clinical depression with glycemic control among patients with type 2 diabetes. Diabetes Care. 2010;33(5):1034–6 http://care.diabetesjournals.org/lookup/doi/10.2337/dc09-2175.
8. Hussain S, Abib A, Singh A, Akhtar M, Najmi AK. Prevalence of depression among type 2 diabetes mellitus patients in India: a meta-analysis. Psychiatry Res. 2018;270:264–73. https://linkinghub.elsevier.com/retrieve/pii/S0165188918306887. https://doi.org/10.1016/j.psychres.2018.09.037.
9. Nanayakkara N, Pease A, Rhayesh S, Eddy T, Schirmer S, Anderson AO, Bernhardt T. Depression and diabetes distress in adults with type 2 diabetes: results from the Australian National Diabetes Audit (ANDA) 2016. Sci Rep. 2018;8(1): 7846. https://www.nature.com/articles/s41598-018-26138-5. https://doi.org/10.1038/s41598-018-26138-5.
10. Keider KE. Diabetes distress or major depressive disorder? A practical approach to diagnosing and treating psychological comorbidities of diabetes. Diabetes Ther. 2017;8(1):1–7. http://link.springer.com/article/10.1007/s13416-017-0231-1.
11. International Diabetes Federation. IDF Diabetes Atlas, Brussels, Belgium. 2019 [cited 2021 May 25]. https://diabetesatlas.org/atlas/ninth-edition/.
12. Kamrul-Hasan AB, Palash-Molla M, Mainul-Ahsan M, Gaffar Aj, Asaduzzaman M, Safluddin M, et al. Prevalence and predictors of depression among patients with type 2 diabetes: a multicenter cross-sectional study from
13. Islam SMS, Rawal LB, Niessen LW. Prevalence of depression and its associated factors in patients with type 2 diabetes: a cross-sectional study in Dhaka. Bangladesh Asian J Psychiatr. 2015;17:36–41. https://linkinghub.elsevier.com/retrieve/pii/S1876201815001665. https://doi.org/10.1016/j.ajp.2015.07.008.

14. WHO. World Health Organization. World Health Organization: WHO STEPSwise approach to NCD risk factor surveillance. Geneva: Surveillance and Population-Based Prevention, Prevention of Noncommunicable Diseases Department. https://www.who.int/ncds/surveillance/steps/GPAQ/en/

15. Asaad G, Sadegian M, Lau R, Xu Y, Soria-Contreras D, Bell R, et al. The reliability and validity of the perceived dietary adherence questionnaire for people with type 2 diabetes. Nutrients. 2015;7(7):5484–96. http://www.mdpi.com/2072-6643/7/7/5231. https://doi.org/10.3390/nu7075231.

16. WHO. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157–63. https://linkinghub.elsevier.com/retrieve/pii/S0140673603152683. https://doi.org/10.1016/S0140-6736(03)15268-3.

17. Grundy SM. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation. 2002;106(25):3143–421. https://www.ahajournals.org/doi/10.1161/circ.106.25.3143.

18. Polonsky WH, Fisher L, Earles J, Dudi RJ, Lees J, Mullan J, et al. Assessing psychosocial distress in diabetes: development of the diabetes distress scale. Diabetes Care. 2005;28(3):626–31 http://care.diabetesjournals.org/cgi/doi/10.2337/diacare.28.3.626.

19. Fisher L, Hessler DM, Polonsky WH, Mullan J. When is diabetes distress clinically meaningful?: establishing cut points for the diabetes distress scale. Diabetes Care. 2012;35(2):259–64 http://diabetesjournals.org/cgi/doi/10.2337/dc11-1572.

20. Spitzer RL. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. JAMA. 1999;282(18):1737. http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.282.18.1737–44.

21. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9. J Gen Intern Med. 2001;16(9):606–13 http://link.springer.com/10.1046/j.1525-1497.2001.01609606.x.

22. Islam M, Karim M, Habib S, Yesmin K. Diabetes distress among type 2 diabetic patients. Int J Med Biomed Res. 2013;2(2):113–24. http://www.ijmbr.com/reviewed/2.2.4.pdf. https://doi.org/10.14194/ijmbr.224.

23. Chew B-H, Vos R, Mohd-Sidik S, Rutten GEHM. Diabetes-Related Distress, Depression and Distress-Depression among Adults with Type 2 Diabetes Mellitus in Malaysia. PLoS One. 2016;11(3):e0152095 https://dx.plos.org/10.1371/journal.pone.0152095.

24. Wong EM, Afshar R, Qian H, Zhang M, Elliott TG, Tang TS. Diabetes distress, depression and glycemic control in a Canadian-based specialty care setting. Can J Diabetes. 2017;41(4):362–5. https://linkinghub.elsevier.com/retrieve/pii/S1499267116308305. https://doi.org/10.1016/j.jcjd.2016.11.006.

25. Darwish L, Beroncal E, Sison MV, Swar dg n e w a Becker W. Depression in people with type 2 diabetes: current perspectives. Diabetes Metab Syndr Obes Targets Ther [Internet]. 2018;11:333–43 https://www.dovepress.com/depression-in-people-with-type-2-diabetes-current-perspectives-peer-reviewed-article-DMSTO.

26. Todd RIG, de Groot M, Golden SH. Diabetes and depression. Curr Diabetes Rep. 2014;14(6):491 http://link.springer.com/10.1007/s11892-014-0491-3.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.